title: Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone.
abstract: OBJECTIVE
  Pretreatment with oral tadenan (TAD) has been shown to possess a protective effect on bladder dysfunction-induced obstruction. We evaluated the functional influence of cotreatment and post-treatment with oral TAD on the frequency/volume characteristics of micturition of conscious rats stimulated with exogenous dihydrotestosterone (DHT) to induce experimental prostate growth.
  
  
  METHODS
  Studies were done on 36 adult Sprague-Dawley male rats, treated daily for 6 weeks and grouped as follows: group 1, sesame oil during weeks 1 and 2, peanut oil during weeks 3 to 6; group 2, DHT (1.25 mg/kg subcutaneously) dissolved in sesame oil as vehicle during weeks 1 and 2 and peanut oil during weeks 3 to 6; group 3, DHT (1.25 mg/kg subcutaneously) dissolved in sesame oil as vehicle and TAD (100 mg/kg orally) in peanut oil during weeks 1 and 2 and TAD during weeks 3 to 6; and group 4, DHT in sesame oil during weeks 1 and 2 and TAD in peanut oil during weeks 3 to 6. The characteristics of frequency/volume were monitored biweekly and at the sixth week.
  
  
  RESULTS
  Controls showed no significant changes from baseline values in volume or frequency during the entire study period. DHT treatment produced a significant increase in frequency (1.9 +/- 0.3 to 3.0 +/- 0.4/hr) and a significant decrease in volume (1.8 +/- 0.3 to 1.2 +/- 0.1 mL). In groups 3 and 4, no significant changes occurred in frequency or volume. By the sixth week of observation, the effects of DHT treatment decreased to control values in all groups. A significant increase in prostatic weight (1191 +/- 11 to 1434 +/- 17 mg/kg) was produced by DHT treatment and TAD cotreatment suppressed growth to 1390 +/- 8.4 mg/kg.
  
  
  CONCLUSIONS
  TAD cotreatment or post-treatment suppressed the effects of DHT on micturition, and TAD cotreatment regressed a developing increase in prostatic weight. Post-treatment TAD administration did not reduce already established growth.
authors.affiliation: Department of Urology, Fukushima Medical University, Fukushima, Japan.
authors.forename: Yosh
authors.initials: Y
authors.lastname: Yoshimura
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamaguchi
authors.forename: Francois
authors.initials: F
authors.lastname: Bellamy
authors.forename: Christos E
authors.initials: CE
authors.lastname: Constantinou
mesh_terms: D000818:Animals; D013196:Dihydrotestosterone / Q000494:pharmacology*; D005233:Fatty Alcohols / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010936:Plant Extracts / Q000494:pharmacology*; D011467:Prostate / Q000033:anatomy & histology / Q000187:drug effects* / Q000254:growth & development*; D000068218:Prunus africana / Q000737:chemistry*; D051381:Rats; D017207:Rats, Sprague-Dawley; D001743:Urinary Bladder / Q000033:anatomy & histology / Q000187:drug effects; D014554:Urination / Q000187:drug effects*; D014563:Urodynamics / Q000187:drug effects
chemical_list: D005233:Fatty Alcohols; D006131:Growth Inhibitors; D010936:Plant Extracts; C009375:Tadenan; D013196:Dihydrotestosterone